Ethiozin

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598553

CAS#: 64529-56-2

Description: Ethiozin is a selective pre- and post-emergence herbicide.

Chemical Structure

img
Ethiozin
CAS# 64529-56-2
Instruction

Theoretical Analysis

MedKoo Cat#: 598553
Name: Ethiozin
CAS#: 64529-56-2
Chemical Formula: C9H16N4OS
Exact Mass: 228.10
Molecular Weight: 228.310
Elemental Analysis: C, 47.35; H, 7.06; N, 24.54; O, 7.01; S, 14.04

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Ethiozin; SMY 1500; SMY-1500; SMY1500; Lektan; Tycor; BAY dic 1559;

IUPAC/Chemical Name: 4-amino-6-(tert-butyl)-3-(ethylthio)-1,2,4-triazin-5(4H)-one

InChi Key: ADZSGNDOZREKJK-UHFFFAOYSA-N

InChi Code: InChI=1S/C9H16N4OS/c1-5-15-8-12-11-6(9(2,3)4)7(14)13(8)10/h5,10H2,1-4H3

SMILES Code: O=C1N(N)C(SCC)=NN=C1C(C)(C)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 228.31 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Nesterenko VV, Anyukhovsky EP, Bugrij EM, Starmer CF, Beloshapko GG, Makielski JC, Kuzmin AV, Menshikov MJu, Mazaev AV, Rosenshtraukh LV. Combination ethacizin and ethmozin treatment of resistant ventricular ectopy: theoretical, experimental, and clinical study. J Cardiovasc Pharmacol. 1994 Mar;23(3):501-8. PubMed PMID: 7515997.

2: Makielski JC, Nesterenko VV, Nelson WL, Undrovinas AI, Starmer CF, Rosenshtraukh LV. State dependence of ethacizin and ethmozin block of sodium current in voltage clamped and internally perfused cardiac Purkinje cells. J Pharmacol Exp Ther. 1990 Jun;253(3):1110-7. PubMed PMID: 2162945.

3: Hewett K, Gessman L, Rosen MR. Effects of procaine amide, quinidine and ethmozin on delayed afterdepolarizations. Eur J Pharmacol. 1983 Dec 9;96(1-2):21-8. PubMed PMID: 6363102.

4: Tsuji Y, Nishimura M, Osada M, Watanabe Y. Membrane action of ethmozin on normoxic and hypoxic canine Purkinje fibers. J Cardiovasc Pharmacol. 1983 Nov-Dec;5(6):961-7. PubMed PMID: 6196568.

5: Rakovec P, Jakopin J, Rode P, Kenda MF, Horvat M. Electrophysiological effects of ethmozin on sinus nodal function in patients with and without sinus node dysfunction. Eur Heart J. 1984 Mar;5(3):243-6. PubMed PMID: 6373266.

6: Fan Z. [The blocking effect of ethmozin on sodium current in single myocardial cell]. Zhonghua Xin Xue Guan Bing Za Zhi. 1990 Aug;18(4):235-7, 255. Chinese. PubMed PMID: 1964893.

7: Urthaler F, Rosenshtraukh LV, Hageman GR, Anjukhovsky EP, James TN. Differential modulation of autonomic activity by ethmozin and ethacizin (analog of ethmozin) on the canine sinus node and atrioventricular junction. J Am Coll Cardiol. 1986 Jul;8(1 Suppl A):86A-94A. PubMed PMID: 3519734.

8: Makielski JC, Undrovinas AI, Hanck DA, Sheets MF, Nesterenko VV, Alpert LA, Rosenshtraukh LV, Fozzard HA. Use-dependent block of sodium current by ethmozin in voltage-clamped internally perfused canine cardiac Purkinje cells. J Mol Cell Cardiol. 1988 Mar;20(3):255-65. PubMed PMID: 2456399.

9: Chazov EI, Rosenshtraukh LV, Shugushev KK. Ethmozin. II. Effects of intravenous drug administration on atrioventricular nodal reentrant tachycardia. Am Heart J. 1984 Sep;108(3 Pt 1):483-9. PubMed PMID: 6382989.

10: Mann DE, Luck JC, Herre JM, Magro SA, Yepsen SC, Griffin JC, Pratt CM, Wyndham CR. Electrophysiologic effects of ethmozin in patients with ventricular tachycardia. Am Heart J. 1984 Apr;107(4):674-9. PubMed PMID: 6367405.

11: Shugushev KKh, Rosenshtraukh LV, Smetnev AS. Electrophysiologic effects of ethmozin on sinus node function in patients with and without sinus node dysfunction. Clin Cardiol. 1986 Sep;9(9):443-8. PubMed PMID: 3530571.

12: Undrovinas AI, Burnashev NA, Makielski D, Rozenshtraukh LV. [Frequency-dependent blocking of single Na channels of cardiomyocytes with ethmozin]. Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR. 1987;10(2):93-6. Russian. PubMed PMID: 2447914.

13: Arnsdorf MF, Sawicki GJ. Effects of ethmozin on excitability in sheep Purkinje fibers: the balance among active and passive cellular properties which comprise the electrophysiologic matrix. J Pharmacol Exp Ther. 1989 Mar;248(3):1158-66. PubMed PMID: 2495352.

14: Poirier JM. Sensitive high performance liquid chromatographic analysis of ethmozin in plasma. Ther Drug Monit. 1985;7(4):439-41. PubMed PMID: 3909535.

15: Whitney CC, Weinstein SH, Gaylord JC. High-performance liquid chromatographic determination of ethmozin in plasma. J Pharm Sci. 1981 Apr;70(4):462-3. PubMed PMID: 7014830.

16: Dangman KH, Hoffman BF. Antiarrhythmic effects of ethmozin in cardiac Purkinje fibers: suppression of automaticity and abolition of triggering. J Pharmacol Exp Ther. 1983 Dec;227(3):578-86. PubMed PMID: 6317840.

17: Chazov EI, Shugushev KK, Rosenshtraukh LV. Ethmozin. I. Effects of intravenous drug administration on paroxysmal supraventricular tachycardia in the ventricular preexcitation syndrome. Am Heart J. 1984 Sep;108(3 Pt 1):475-82. PubMed PMID: 6382988.

18: Fazekas T, Vos MA, Leunissen JD, Wellens HJ. Effects of magnesium and ethmozin on ventricular tachycardia induced by ouabain and ventricular pacing in conscious dogs with complete atrioventricular block. Acta Physiol Hung. 1993;81(1):59-70. PubMed PMID: 8178656.

19: Scamps F, Undrovinas A, Vassort G. Inhibition of ICa in single frog cardiac cells by quinidine, flecainide, ethmozin, and ethacizin. Am J Physiol. 1989 Mar;256(3 Pt 1):C549-59. PubMed PMID: 2538064.

20: Rakovec P, Kenda MF. [Effect of the anti-arrhythmia agent ethmozin on the refractory period of the accessory pathway in Wolff-Parkinson-White syndrome]. Wien Med Wochenschr. 1986 Feb 15;136(3):65-6. German. PubMed PMID: 3515775.